GlassScriptPhysician profile
Salim M Shammo
NPI 1295791937
$1,153.18
in general payments reported to CMS, 2019-2025
13 companies · $38.35 in 2025
The $38.35 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $11.56 · 2021: $142 · 2022: $242 · 2023: $153 · 2024: $326 · 2025: $38.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $266.45 | 2021-2024 | Rotablator Rotational Atherectomy System Console Kit |
| Novartis Pharmaceuticals Corporation | $232.96 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $147.55 | 2019-2022 | |
| Shockwave Medical, INC | $111.29 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $110.83 | 2022-2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $101.98 | 2019-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $52.22 | 2021-2022 | |
| Cardiva Medical, INC. | $31.19 | 2024 | Cardiva Vascade 6/7f Vcs |
| Medtronic Vascular, INC. | $25.40 | 2019 | |
| Daiichi Sankyo INC. | $23.80 | 2019 | |
| Amgen INC. | $22.65 | 2025 | Repatha |
| Novo Nordisk INC | $15.30 | 2023 | Ozempic |
| Getinge USA Sales, LLC | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salim Shammo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.